Abstract
BACKGROUND: Postmastectomy breast edema is a common complication in patients undergoing immediate implant-based reconstruction, leading to physical and psychological consequences. Despite its clinical relevance, standardized prophylactic strategies remain lacking. OBJECTIVES: The authors of this study aim to evaluate the efficacy of an anti-edema formulation containing diosmin, coumarin, and arbutin (Linfadren, Omega Pharma Srl, Italy) in reducing postmastectomy breast edema and improving postoperative outcomes. METHODS: A prospective, randomized clinical trial was conducted at a single tertiary care center. Women aged ≥18 years undergoing mastectomy with immediate implant-based reconstruction were randomized (1:1) into 2 groups: control (standard postoperative prophylaxis) and experimental (standard prophylaxis plus Linfadren, Omega Pharma Srl). Mastectomy flap thickness was measured using Vernier calipers, and breast edema symptoms were assessed with the Breast Edema Questionnaire (BrEQ). Follow-up visits were scheduled weekly during the first month, with additional evaluations at 6 weeks and 2 months. RESULTS: The experimental group demonstrated a significant reduction in mastectomy flap thickness (45.95% decrease at 2 months vs stable or increased thickness in the control group, P < .05). BrEQ scores improved more rapidly in the experimental group, reflecting reduced symptoms of breast edema. Pitting edema prevalence was consistently lower in the experimental group compared with the control group throughout the study (P < .05). CONCLUSIONS: In this study, the authors highlight the potential of Linfadren (Omega Pharma Srl) as an effective prophylactic treatment for postmastectomy breast edema. By mitigating edema, this approach may improve postoperative recovery, reduce complications, and enhance patients' quality of life. Further large-scale studies are warranted to validate these findings.